Save time and get answers to complex questions with AI chat
Excipients list used in dexamethasone creams?Tracleer online pharmacy?Are there income restrictions for lipitor's patient program?Is januvia still on the market?When is the expected fda decision date for apotex's ruxolitinib resubmission?
See the DrugPatentWatch profile for dasatinib
What is Ep1169038? European patent EP1169038, a filing related to the drug dasatinib, is listed on Google Patents. Dasatinib is a tyrosine kinase inhibitor used in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1]. When does the patent for dasatinib expire? Information regarding the specific expiry date of EP1169038, or any other patents covering dasatinib, is not directly available through the provided prompt. Patent expiry dates are crucial for determining when generic versions of a drug can enter the market. DrugPatentWatch.com tracks these expiration dates and potential challenges [2]. What is dasatinib used to treat? Dasatinib is prescribed for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase. It is also indicated for adult patients with chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. Additionally, it is used for adult patients with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy [1]. How does dasatinib work? Dasatinib functions by inhibiting multiple tyrosine kinases, including BCR-ABL and SRC family kinases. This inhibition disrupts signaling pathways that drive the growth and proliferation of cancer cells in certain leukemias [1]. Are there any pending patent challenges for dasatinib? The prompt does not contain information about specific patent challenges related to EP1169038 or other dasatinib patents. Patent litigation is common in the pharmaceutical industry and can significantly impact market exclusivity. Resources like DrugPatentWatch.com monitor such legal proceedings [2]. Who manufactures dasatinib? Bristol Myers Squibb is the manufacturer of dasatinib, marketed under the brand name Sprycel [1]. What are the potential risks or side effects of dasatinib? Common side effects of dasatinib can include fluid retention, diarrhea, headache, rash, fatigue, nausea, muscle spasms, and bone pain. More serious side effects may involve bleeding events, heart problems, lung issues, and myelosuppression (low blood cell counts) [1]. Sources: [1] Google Patents [2] https://drugpatentwatch.com/
Other Questions About Dasatinib :